New and developing non-adrenoreceptor small molecule drugs for the treatment of asthma

References

• 2016 GINA (Global Initiative for Asthma) Report, Global Strategy for Asthma Management and Prevention. 2016. [cited 2016 Dec 12]. Available from: http://www.ginasthma.org/
   Google Scholar
• Montuschi P, Barnes PJ. New perspectives in pharmacological treatment of mild persistent asthma. Drug Discov Today. 2011 Dec;16(23–24):1084–1091.
   PubMed Web of Science ®Google Scholar
• O’Byrne P, Barnes P, Rodriquez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial. Am J Respir Crit Care Med. 2001;164(8):1392–1397.
   PubMed Web of Science ®Google Scholar
• Pauwels R, Pedersen S, Busse W, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet. 2003;361:1071–1076.
   PubMed Web of Science ®Google Scholar
• Stempel DA, Raphiou IH, Kral KM, et al. Serious asthma events with fluticasone plus salmeterol versus fluticasone alone. N Eng J Med. 2016;374(19):1822–1830.
   PubMed Web of Science ®Google Scholar
• Peters SP, Bleecker ER, Canonica GW, et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. N Eng J Med. 2016;375(9):850–860.
   PubMed Web of Science ®Google Scholar
• Montuschi P. Leukotrienes, antileukotrienes and asthma. Mini Rev Med Chem. 2008;8(7):647–656.
   PubMed Web of Science ®Google Scholar
• BTS/SIGN British Guideline on the Management of Asthma. 2016. Available from: www.sign.ac.uk
   Google Scholar
• Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the Recognise Asthma and Link to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med. 2014;24:14009.
   PubMed Web of Science ®Google Scholar
• Demoly P, Annunziata K, Gubba E, et al. Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years. Eur Respir Rev. 2012 Mar 1;21(123):66–74.
   PubMedGoogle Scholar
• Kistemaker LEM, Gosens R. Acetylcholine beyond bronchoconstriction: roles in inflammation and remodeling. Trends Pharmacol Sci. 2015;36(3):164–171.
   PubMed Web of Science ®Google Scholar
• Montuschi P, Macagno F, Valente S, et al. Inhaled muscarinic acetylcholine receptor antagonists for treatment of COPD. Curr Med Chem. 2013;20(12):1464–1476.
   PubMed Web of Science ®Google Scholar
• Montuschi P, Ciabattoni G. Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends. J Med Chem. 2015 May 28;58(10):4131–4164.
   PubMed Web of Science ®Google Scholar
• Anderson DE, Kew KM, Boyter AC. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthma. Cochrane Database Syst Rev. 2015;(8):CD011397. doi: 10.1002/14651858.CD011397.pub2.
   Google Scholar
• Hamelmann E, Bateman ED, Vogelberg C, et al. Tiotropium add-on therapy in adolescents with moderate asthma: a 1-year randomized controlled trial. J Allergy Clin Immunol. 2016 Aug;138(2):441–50.e8.
   PubMed Web of Science ®Google Scholar
• Hamelmann E, Bernstein JA, Vandewalker M, et al. A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma. Eur Respir J. 2017;49:1601100.
   PubMed Web of Science ®Google Scholar
• Evans DJW, Kew KM, Anderson DE, et al. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma. Cochrane Database Syst Rev. 2015;(7):CD011437. doi:10.1002/14651858.CD011437.pub2.
   Google Scholar
• Peters SP, Kunselman SJ, Icitovic N, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med. 2010;363(18):1715–1726.
   PubMed Web of Science ®Google Scholar
• Kerstjens HAM, Casale TB, Bleecker ER, et al. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. Lancet Respir Med. 2015;3(5):367–376.
   PubMed Web of Science ®Google Scholar
• Kew KM, Evans DJW, Allison DE, et al. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthma. Cochrane Database Syst Rev. 2015;(6):CD011438. doi: 10.1002/14651858.CD011438.pub2.
   Web of Science ®Google Scholar
• Kerstjens HAM, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012;367(13):1198–1207.
   PubMed Web of Science ®Google Scholar
• Kew KM, Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst Rev. 2016;(1):CD011721. doi:10.1002/14651858.CD011721.pub2.
   Web of Science ®Google Scholar
• Ohta K, Ichinose M, Tohda Y, et al. Long-term once-daily tiotropium Respimat® is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: a randomised, placebo-controlled study. PLoS ONE. 2015;10(4):e0124109.
   PubMed Web of Science ®Google Scholar
• Price D, Kaplan A, Jones R, et al. Long-acting muscarinic antagonist use in adults with asthma: real-life prescribing and outcomes of add-on therapy with tiotropium bromide. J Asthma Allergy. 2015 Jan 14;8:1–13.
   PubMed Web of Science ®Google Scholar
• Peters SP, Bleecker ER, Kunselman SJ, et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. J Allergy Clin Immunol. 2013 Sep 30;132(5):1068–1074.
   PubMed Web of Science ®Google Scholar
• Kerstjens HAM, Moroni-Zentgraf P, Tashkin DP, et al. Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status. Respir Med. 2016 Aug;117:198–206.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Kornmann O, Schmidt P, et al. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. J Allergy Clin Immunol. 2011;128(2):315–322.
   PubMed Web of Science ®Google Scholar
• Dahl R, Engel M, Dusser D, et al. Safety and tolerability of once-daily tiotropium Respimat® as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: a pooled safety analysis. Respir Med. 2016;118:102–111.
   PubMed Web of Science ®Google Scholar
• Wise RA. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med. 2013;369:1491–1501.
   PubMed Web of Science ®Google Scholar
• Tiotropium delivered via Respimat compared with Handihaler: no significant difference in mortality in TIOSPIR trial Drug Safety Update. 2015 [cited 2016 Dec 12]. Available from: https://www.gov.uk/drug-safety-update/tiotropium-delivered-via-respimat-compared-with-handihaler-no-significant-difference-in-mortality-in-tiospir-trial
   Google Scholar
• Lee LA, Yang S, Kerwin E, et al. The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose-ranging study. Respir Med. 2015;109(1):54–62.
   PubMed Web of Science ®Google Scholar
• Lee LA, Briggs A, Edwards LD, et al. A randomized, three-period crossover study of umeclidinium as monotherapy in adult patients with asthma. Respir Med. 2015;109(1):63–73.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov Registry: A service of the U.S. National Institutes of Health. 2016. [cited 2016 Dec 12]. Available from: https://clinicaltrials.gov/
   Google Scholar
• Singh D, Cadden P, Hunter M, et al. Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459. Eur Respir J. 2013 Jan 1;41(1):46–52.
   PubMed Web of Science ®Google Scholar
• Diamant Z, Sidharta PN, Singh D, et al. Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics. Clin Exp Allergy. 2014;44(8):1044–1052.
   PubMed Web of Science ®Google Scholar
• Barnes N, Pavord I, Chuchalin A, et al. A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. Clin Exp Allergy. 2012;42(1):38–48.
   PubMed Web of Science ®Google Scholar
• Pettipher R, Hunter MG, Perkins CM, et al. Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459. Allergy. 2014;69(9):1223–1232.
   PubMed Web of Science ®Google Scholar
• Hall IP, Fowler AV, Gupta A, et al. Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment. Pulm Pharm Therap. 2015;32:37–44.
   PubMed Web of Science ®Google Scholar
• Kuna P, Bjermer L, Tornling G. Two phase II randomized trials on the CRTh2 antagonist AZD1981 in adults with asthma. Drug Des Devel Ther. 2016 Aug 31;10:2759–2770.
   PubMed Web of Science ®Google Scholar
• Busse WW, Wenzel SE, Meltzer EO, et al. Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients. J Allergy Clin Immunol. 2013;131(2):339–345.
   PubMed Web of Science ®Google Scholar
• Erpenbeck VJ, Popov TA, Miller D, et al. The oral CRTh2 antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthma. Pulm Pharm Therap. 2016;39:54–63.
   PubMed Web of Science ®Google Scholar
• Gonem S, Berair R, Singapuri A, et al. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med. 2016;4(9):699–707.
   PubMed Web of Science ®Google Scholar
• Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet. 2005 [2015 Jan 21];365(9454):167–175.
   PubMed Web of Science ®Google Scholar
• Kim SW, Kim JH, Park CK, et al. Effect of roflumilast on airway remodeling in a murine model of chronic asthma. Clin Exp Allergy. 2016;46(5):754–763.
   PubMed Web of Science ®Google Scholar
• Page CP. Phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. Int Arch Allergy Immunol. 2014;165(3):152–164.
   PubMed Web of Science ®Google Scholar
• Gauvreau G, Boulet L-P, Schmid-Wirlitsch C, et al. Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects. Respir Res. 2011;12(1):140.
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Chervinsky P, Busse W, et al. Roflumilast for asthma: efficacy findings in placebo-controlled studies. Pulm Pharm Therap. 2015;35:Supplement:S20–S27.
   Web of Science ®Google Scholar
• Bateman ED, Goehring U-M, Richard F, et al. Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma. J Allergy Clin Immunol. 2016 Jul;138(1):142–49.e8.
   PubMed Web of Science ®Google Scholar
• Chervinsky P, Meltzer EO, Busse W, et al. Roflumilast for asthma: safety findings from a pooled analysis of ten clinical studies. Pulm Pharm Therap. 2015;35:Supplement:S28–S34.
   Web of Science ®Google Scholar
• Chapman RW, House A, Richard J, et al. Pharmacology of a potent and selective inhibitor of PDE4 for inhaled administration. Eur J Pharmacol. 2010;643(2–3):274–281.
   PubMed Web of Science ®Google Scholar
• Moretto N, Caruso P, Bosco R, et al. CHF6001, a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration. J Pharmacol Exp Ther. 2015 Jan 9;352(3):559–567.
   PubMed Web of Science ®Google Scholar
• De Savi C, Cox RJ, Warner DJ, et al. Efficacious inhaled PDE4 inhibitors with low emetic potential and long duration of action for the treatment of COPD. J Med Chem. 2014 Apr;[2015 Jan16];57(11):4661–4676.
   PubMed Web of Science ®Google Scholar
• Singh D, Petavy F, Macdonald A, et al. The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma. Resp Res. 2010;11(1):26.
   PubMed Web of Science ®Google Scholar
• Singh D, Leaker B, Boyce M, et al. A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients. Pulm Pharm Therap. 2016 Oct;40:1–6.
   PubMed Web of Science ®Google Scholar
• Franciosi LG, Diamant Z, Banner KH, et al. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respir Med. 2013 Nov 1;1(9):714–727.
   PubMed Web of Science ®Google Scholar
• Bjermer L, Stewart J, Abbott-Banner K, et al. RPL554, a first-in-class dual phosphodiesterase (PDE)3/4 inhibitor, is equi-effective as a bronchodilator to maximal doses of salbutamol in asthmatics but with fewer adverse events. Am J Resir Crit Care Med. 2016;193:A7770–A70.
   Web of Science ®Google Scholar
• Chapman RW, Phillips JE, Hipkin RW, et al. CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol Ther. 2009;121(1):55–68.
   PubMed Web of Science ®Google Scholar
• Thomson NC. Novel approaches to the management of noneosinophilic asthma. Therap Adv Respir Dis. 2016 Feb 28;10(3):211–234.
   PubMed Web of Science ®Google Scholar
• Nair P, Gaga M, Zervas E, et al. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin Exp Allergy. 2012;42(7):1097–1103.
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, Metev H, Puu M, et al. Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2016;10:797–806.
   Web of Science ®Google Scholar
• Cohen S, Fleischmann R. Kinase inhibitors: a new approach to rheumatoid arthritis treatment. Curr Opin Rheumatol. 2010;22(3):330–335.
   PubMed Web of Science ®Google Scholar
• Hammaker D, Firestein G. “Go upstream, young man”: lessons learned from the p38 saga. Ann Rheum Dis. 2010;69(Suppl 1):i77–82.
   PubMed Web of Science ®Google Scholar
• Bhavsar P, Khorasani N, Hew M, et al. Effect of p38 MAPK inhibition on corticosteroid suppression of cytokine release in severe asthma. Eur Respir J. 2010 April 1;35(4):750–756.
   PubMed Web of Science ®Google Scholar
• Guntur VP, Reinero CR. The potential use of tyrosine kinase inhibitors in severe asthma. Curr Opin Allergy Clin Immunol. 2012;12(1):68–75.
   PubMed Web of Science ®Google Scholar
• Chung KF p38 mitogen-activated protein kinase pathways in asthma and COPD. Chest. 2011 Jun 1;139(6):1470–1479.
   PubMed Web of Science ®Google Scholar
• Mercado N, Hakim A, Kobayashi Y, et al. Restoration of corticosteroid sensitivity by p38 mitogen activated protein kinase inhibition in peripheral blood mononuclear cells from severe asthma. PLoS ONE. 2012;7(7):e41582.
   PubMed Web of Science ®Google Scholar
• Berlin AA, Lukacs NW Treatment of cockroach allergen asthma model with imatinib attenuates airway responses. Am J Respir Crit Care Med. 2005 Jan 1 [2014 Dec 7];171(1):35–39.
   PubMed Web of Science ®Google Scholar
• Rhee CK, Kim JW, Park CK, et al. Effect of imatinib on airway smooth muscle thickening in a murine model of chronic asthma. Int Arch Allergy Immunol. 2011;155(3):243–251.
   PubMed Web of Science ®Google Scholar
• Humbert M, De Blay F, Garcia G, et al. Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics. Allergy. 2009;64(8):1194–1201.
   PubMed Web of Science ®Google Scholar
• Schacke H, Schottelius A, Docke W-D, et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. PNAS. 2004 Jan 6;101(1):227–232.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Coppola A, Rogliani P, et al. Novel glucocorticoid receptor agonists in the treatment of asthma. Expert Opin Investig Drugs. 2015;24(11):1473–1482.
   PubMed Web of Science ®Google Scholar
• Sundahl N, Bridelance J, Libert C, et al. Selective glucocorticoid receptor modulation: new directions with non-steroidal scaffolds. Pharmacol Therapeut. 2015 Aug;152:28–41.
   PubMed Web of Science ®Google Scholar
• Clark AR, Belvisi MG. Maps and legends: the quest for dissociated ligands of the glucocorticoid receptor. Pharmacol Ther. 2012;134(1):54–67.
   PubMed Web of Science ®Google Scholar
• Leaker BR, O’Connor B, Singh D, et al. The novel inhaled glucocorticoid receptor agonist GW870086X protects against adenosine-induced bronchoconstriction in asthma. J Allergy Clin Immunol. 2015 Aug;136(2):501–02.e6.
   PubMed Web of Science ®Google Scholar
• Bareille P, Hardes K, Donald AC. Efficacy and safety of once-daily GW870086 a novel selective glucocorticoid in mild-moderate asthmatics: a randomised, two-way crossover, controlled clinical trial. J Asthma. 2013 Dec 1;50(10):1077–1082.
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, Boulet L-P, Leigh R, et al. A nonsteroidal glucocorticoid receptor agonist inhibits allergen-induced late asthmatic responses. Am J Resp Crit Care Med. 2015 Dec 4 [2015 Jan 16];191(2):161–167.
   PubMed Web of Science ®Google Scholar
• Gielen V, Johnston SL, Edwards MR. Azithromycin induces anti-viral responses in bronchial epithelial cells. Eur Respir J. 2010 Feb 11;36(3):646–654.
   PubMed Web of Science ®Google Scholar
• Schögler A, Kopf BS, Edwards MR, et al. Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells. Eur Respir J. 2015 Feb 1;45(2):428–439.
   PubMed Web of Science ®Google Scholar
• Cameron EJ, McSharry C, Chaudhuri R, et al. Long-term macrolide treatment of chronic inflammatory airway diseases: risks, benefits and future developments. Clin Exp Allergy. 2012;42(9):1302–1312.
   PubMed Web of Science ®Google Scholar
• Culic O, Erakovic V, Parnham MJ. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol. 2001;429(1–3):209–229.
   PubMed Web of Science ®Google Scholar
• Fujitani Y, Trifilieff A. In vivo and in vitro effects of SAR 943, a rapamycin analogue, on airway inflammation and remodeling. Am J Respir Crit Care Med. 2003 Jan 15;167(2):193–198.
   PubMed Web of Science ®Google Scholar
• Simpson JL, Powell H, Boyle MJ, et al. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med. 2008 Jan 15;177(2):148–155.
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Wada H, Rossios C, et al. A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-κB inhibition. J Pharmacol Exp Ther. 2013 Apr 1;345(1):76–84.
   PubMed Web of Science ®Google Scholar
• Essilfie A-T, Horvat JC, Kim RY, et al. Macrolide therapy suppresses key features of experimental steroid-sensitive and steroid-insensitive asthma. Thorax. 2015 May 1;70(5):458–467.
   PubMed Web of Science ®Google Scholar
• Spahn J, Fost D, Covar R, et al. Clarithromycin potentiates glucocorticoid responsiveness in patients with asthma: results of a pilot study. Ann Allergy Asthma Immunol. 2001;87(6):501–505.
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Wada H, Rossios C, et al. A novel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition. Br J Pharmacol. 2013;169(5):1024–1034.
   PubMed Web of Science ®Google Scholar
• Hao M, Lin J, Shu J, et al. Clarithromycin might attenuate the airway inflammation of smoke-exposed asthmatic mice via affecting HDAC2. J Thorac Dis. 2015;7(7):1189–1197.
   PubMed Web of Science ®Google Scholar
• Kew K, Undela K, Kotorts I, et al. Macrolides for chronic asthma. Cochrane Database Syst Rev. 2015;15(9):CD002997.
   Google Scholar
• Balloy V, Deveaux A, Lebeaux D, et al. Azithromycin analogue CSY0073 attenuates lung inflammation induced by LPS challenge. Br J Pharmacol. 2014;171(7):1783–1794.
   PubMed Web of Science ®Google Scholar
• Porter JD, Watson J, Roberts LR, et al. Identification of novel macrolides with antibacterial, anti-inflammatory and type I and III IFN-augmenting activity in airway epithelium. J Antimicrob Chemother. 2016 Jul 25];71(10):2767–2781.
   PubMed Web of Science ®Google Scholar
• Brusselle GG, VanderStichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax. 2013 Apr 1];68(4):322–329.
   PubMed Web of Science ®Google Scholar
• Cameron EJ, Chaudhuri R, Mair F, et al. Randomised controlled trial of azithromycin in smokers with asthma. Eur Respir J. 2013 Nov 1;42(5):1412–1415.
   PubMed Web of Science ®Google Scholar
• Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol. 2006;6(5):358–370.
   PubMed Web of Science ®Google Scholar
• Samson K, Minoguchi K, Tanaka A, et al. Inhibitory effects of fluvastatin on cytokine and chemokine production by peripheral blood mononuclear cells in patients with allergic asthma. Clin Exp Allergy. 2006;36(4):475–482.
   PubMed Web of Science ®Google Scholar
• Maneechotesuwan K, Ekjiratrakul W, Kasetsinsombat K, et al. Statins enhance the anti-inflammatory effects of inhaled corticosteroids in asthmatic patients through increased induction of indoleamine 2, 3-dioxygenase. J Allergy Clin Immunol. 2010;126(4):754–762.
   PubMed Web of Science ®Google Scholar
• Hothersall E, McSharry C, Thomson NC. Potential therapeutic role for statins in respiratory disease. Thorax. 2006;61(8):729–734.
   PubMed Web of Science ®Google Scholar
• Yeganeh B, Wiechec E, Ande S, et al. Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease. Pharmacol Ther. 2014;143(1):87–110.
   PubMed Web of Science ®Google Scholar
• McKay A, Leung BP, McInnes IB, et al. A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J Immunol. 2004;172(5):2903–2908.
   PubMed Web of Science ®Google Scholar
• Zeki AA, Franzi L, Last J, et al. Simvastatin inhibits airway hyperreactivity: implications for the mevalonate pathway and beyond. Am J Respir Crit Care Med. 2009 Oct 15;180(8):731–740.
   PubMed Web of Science ®Google Scholar
• Thomson NC. Clinical studies of statins in asthma and COPD. Curr Mol Pharmacol. 2016;9:1–12.
   Google Scholar
• Braganza G, Chaudhuri R, McSharry C, et al. Effects of short-term treatment with atorvastatin in smokers with asthma – a randomized controlled trial. BMC Pulm Med. 2011;11:16.
   PubMed Web of Science ®Google Scholar
• Thomson NC, Charron CE, Chaudhuri R, et al. Atorvastatin in combination with inhaled beclometasone modulates inflammatory sputum mediators in smokers with asthma. Pulm Pharmacol Ther. 2015;31:1–8.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Role of HDAC2 in the pathophysiology of COPD. Annu Rev Physiol. 2009;71(1):451–464.
   PubMed Web of Science ®Google Scholar
• To Y, Ito K, Kizawa Y, et al. Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010 Oct 1;182(7):897–904.
   PubMed Web of Science ®Google Scholar
• Spears M, Donnelly I, Jolly L, et al. Effect of low-dose theophylline plus beclometasone on lung function in smokers with asthma: a pilot study. Eur Respir J. 2009 May 1;33(5):1010–1017.
   PubMed Web of Science ®Google Scholar
• Vectura Group plc :: Results of the Annual General Meeting. 2016. [cited 2016 Dec 12]. Available from: http://www.vectura.com/news/results-annual-general-meeting/
   Google Scholar
• Fajt ML, Wenzel SE. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. J Allergy Clin Immunol. 2015;135(2):299–310.
   PubMed Web of Science ®Google Scholar
• Shaw DE, Sousa AR, Fowler SJ, et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J. 2015 [2015 Nov 1];46(5):1308–1321.
   PubMed Web of Science ®Google Scholar
• Gaga M, Brand PLP, Thomson NC. The quest for the grail: multidimensional efforts for understanding and targeting severe asthma. Eur Respir J. 2015;46(5):1227–1231.
   PubMed Web of Science ®Google Scholar
• Heaney LG, Djukanovic R, Woodcock A, et al. Research in progress: medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK). Thorax. 2016 Jul 23;71(1):187–189.
   PubMed Web of Science ®Google Scholar